Migraine drug safety in pregnancy under scrutiny

NCT ID NCT05158894

Recruiting now Knowledge-focused Sponsor: AbbVie Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This observational study tracks the safety of Ubrelvy and Qulipta, two migraine drugs, when used during pregnancy. Researchers will follow about 1,884 pregnant women with migraine in the US and Canada, comparing those who take either drug to a group who does not. The goal is to see if these medications affect pregnancy outcomes or infant health up to 12 months after birth.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Ubrogepant (Ubrelvy) and Atogepant (Qulipta)
What this could lead to: If successful, this study could provide important safety information about using these migraine drugs during pregnancy, helping doctors and patients make informed decisions.
What could go wrong: This is an observational registry, not a controlled trial, so it cannot prove cause and effect. Results depend on real-world reporting and may take years to complete.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MIGRAINE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

migraine disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MIGRAINE

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Iqvia /Id# 266904
RECRUITING

Durham, North Carolina, 27703-8426, United States
Ottawa Hospital Research Institute /ID# 280174
RECRUITING

Ottawa, Ontario, K1Y 4E9, Canada

Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.